Dr. Jason Gaglia, Dr.
Claim this profileJoslin Diabetes Center
Area of expertise
Type 1 Diabetes
Jason Gaglia, Dr. has run 7 trials for Type 1 Diabetes. Some of their research focus areas include:
Diabetes
Jason Gaglia, Dr. has run 3 trials for Diabetes.
Affiliated Hospitals
Joslin Diabetes Center
Joslin Diabetes Center, Harvard Medical School
Clinical Trials Jason Gaglia, Dr. is currently running
Observational Study
for Type 1 Diabetes
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for type 1 diabetes in the future.
Recruiting
1 award
N/A
2 criteria
Prevention
for Type 1 Diabetes
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM. Purpose: TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes. The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes.
Recruiting
1 award
N/A
3 criteria
More about Jason Gaglia, Dr.
Clinical Trial Related
5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jason Gaglia, Dr. has experience with
- Placebo
- Ladarixin
- Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated In Alhydrogel®
- Colecalciferol 2000 IU
- Placebo For Recombinant Human Glutamic Acid Decarboxylase (rhGAD65) Formulated In Alhydrogel®
- NNC0361-0041
Breakdown of trials Jason Gaglia, Dr. has run
Type 1 Diabetes
Diabetes
Insulin Resistance
Impaired Glucose Tolerance
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason Gaglia, Dr. specialize in?
Jason Gaglia, Dr. focuses on Type 1 Diabetes and Diabetes. In particular, much of their work with Type 1 Diabetes has involved HLA positive patients, or patients who are GAD65 positive.
Is Jason Gaglia, Dr. currently recruiting for clinical trials?
Yes, Jason Gaglia, Dr. is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Jason Gaglia, Dr. has studied deeply?
Yes, Jason Gaglia, Dr. has studied treatments such as Placebo, Ladarixin, Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®.
What is the best way to schedule an appointment with Jason Gaglia, Dr.?
Apply for one of the trials that Jason Gaglia, Dr. is conducting.
What is the office address of Jason Gaglia, Dr.?
The office of Jason Gaglia, Dr. is located at: Joslin Diabetes Center, Boston, Massachusetts 02215 United States. This is the address for their practice at the Joslin Diabetes Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.